Carcinoids, GISTs, and Lymphomas of Colon and Rectum
Less common tumors of the colon and rectum include carcinoids, gastrointestinal stromal tumors, and gastrointestinal lymphomas. Carcinoids are of neuroectodermal origin and frequently secrete bioactive compounds such as serotonin and histamine. Carcinoids that have metastasized to the liver may cause systemic symptoms referred to the carcinoid syndrome. Treatment of carcinoid tumors is surgical resection; however, the type of resection is dependent on the size and location of the tumor. Adjuvant treatment of carcinoid tumors involves the use of somatostatin analogues. Gastrointestinal stromal tumors occur less frequently in the colon and rectum than in other organs of the intestinal tract, but may be detected during endoscopic evaluation of the colon. Surgical treatment of GISTs also depends on the size and location of the tumor. Adjuvant treatment with imatinib (a tyrosine kinase inhibitor that blocks KIT activation) has been shown to reduce the risk of recurrence. The gastrointestinal tract is the most common site of extranodal lymphoma. Treatment typically involves a combination of surgical resection and systemic chemotherapy.
KeywordsCarcinoid Gastrointestinal stromal tumors (GIST) Lymphoma Colorectum Treatment TMN staging
Transanal resection of a rectal GIST (Courtesy of Rodrigo Perez, M.D.) (MP4 287,260 kb)
- 1.Oberndorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol. 1907;1:7.Google Scholar
- 41.Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897–904.CrossRefGoogle Scholar
- 45.Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.CrossRefGoogle Scholar
- 66.Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32.CrossRefGoogle Scholar
- 67.Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3874–83.CrossRefGoogle Scholar
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 2.5 International License (http://creativecommons.org/licenses/by-nc/2.5/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.